N4-phenyl-quinazoline-4-amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
US-2017252317-A1 · Sep 7, 2017 · US
Quinazoline analogs as receptor tyrosine kinase inhibitors
US10221194B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10221194-B2 |
| Application number | US-201715606928-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 26, 2017 |
| Priority date | Aug 14, 2003 |
| Publication date | Mar 5, 2019 |
| Grant date | Mar 5, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to compounds of Formula 11, and to pharmaceutically acceptable acid addition salts thereof, wherein R 1 —R 3 , R 6 , and X have any of the values defined in the specification. The compounds are suitable as synthetic intermediates for preparing imaging tools.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound selected from the group consisting of:
Assignees
Inventors
Classifications
specific for metastasis · CPC title
Antineoplastic agents · CPC title
Nitrogen atoms · CPC title
containing three or more hetero rings · CPC title
containing three or more hetero rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10221194B2 cover?
- The invention relates to compounds of Formula 11, and to pharmaceutically acceptable acid addition salts thereof, wherein R 1 —R 3 , R 6 , and X have any of the values defined in the specification. The compounds are suitable as synthetic intermediates for preparing imaging tools.
- Who is the assignee on this patent?
- Array Biopharma Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D498/10. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).